Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey
Summary: Background: In January 2018, Ecuador changed its routine immunization schedule by replacing one full dose of inactivated poliovirus vaccine (IPV) administered intramuscularly at 2 months of age with two doses of fractional IPV (1/5th of full dose, fIPV) administered intradermally at 2 and...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-07-01
|
| Series: | The Lancet Regional Health. Americas |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667193X22000527 |
| _version_ | 1818524074884726784 |
|---|---|
| author | Gabriel Trueba Vishali Jeyaseelan Lazaro Lopez Bernardo A. Mainou Yiting Zhang Alvaro Whittembury Alfredo Jose Olmedo Valarezo Gonzalo Baquero Rosa Romero de Aguinaga Lucia Jeannete Zurita Salinas Maria Gabriela Santacruz Mancheno Diana Elizabeth Medina Chacho Emmanuelle Quentin Ana Elena Chevez Gloria Rey-Benito Ondrej Mach |
| author_facet | Gabriel Trueba Vishali Jeyaseelan Lazaro Lopez Bernardo A. Mainou Yiting Zhang Alvaro Whittembury Alfredo Jose Olmedo Valarezo Gonzalo Baquero Rosa Romero de Aguinaga Lucia Jeannete Zurita Salinas Maria Gabriela Santacruz Mancheno Diana Elizabeth Medina Chacho Emmanuelle Quentin Ana Elena Chevez Gloria Rey-Benito Ondrej Mach |
| author_sort | Gabriel Trueba |
| collection | DOAJ |
| description | Summary: Background: In January 2018, Ecuador changed its routine immunization schedule by replacing one full dose of inactivated poliovirus vaccine (IPV) administered intramuscularly at 2 months of age with two doses of fractional IPV (1/5th of full dose, fIPV) administered intradermally at 2 and 4 months of age; and bivalent oral poliovirus vaccine (serotypes 1 and 3, bOPV) continues to be used. We compared seroprevalence and titres of polio antibodies achieved by the past and the current immunization schedules. Methods: This was a cross-sectional serological survey in children in Ecuador who received bOPV and either one IPV dose in 2017 or two fIPV doses in 2018. One blood sample was collected between October 2020 and March 2021 and analysed for presence of poliovirus neutralizing antibodies at CDC, Atlanta by microneutralization assay. Findings: We obtained 321 analysable samples from 329 (97·6%) enrolled children (160 received IPV and 161 fIPV). For serotype 2, seroprevalence was 50·0% (CI95%= 44·2-55·8%) for IPV and 83·2% (CI95%=78·5-87·1%) for fIPV recipients (p<0·001). Median antibody titers for serotype 2 were significantly lower for IPV than for fIPV recipients (3·0, CI95%= 3 – 3·5 vs. 4·8, CI95%= 4·5 – 5·2, p<0·001). Seroprevalence for serotypes 1 and 3 was above 90% and was not significantly different between IPV and fIPV recipients. Interpretation: Ecuador achieved significantly better poliovirus serotype 2 immunogenicity with two fIPV doses than with one IPV dose, while preserving vaccine supply and reducing costs. Our data provide further evidence that fIPV is a beneficial and potentially a cost-effective option in polio immunization. Funding: WHO obtained funds for the study from Rotary International. |
| first_indexed | 2024-12-11T05:52:42Z |
| format | Article |
| id | doaj.art-2ed131346f0c44f2b3226be5ddffe482 |
| institution | Directory Open Access Journal |
| issn | 2667-193X |
| language | English |
| last_indexed | 2024-12-11T05:52:42Z |
| publishDate | 2022-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Regional Health. Americas |
| spelling | doaj.art-2ed131346f0c44f2b3226be5ddffe4822022-12-22T01:18:46ZengElsevierThe Lancet Regional Health. Americas2667-193X2022-07-0111100235Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological surveyGabriel Trueba0Vishali Jeyaseelan1Lazaro Lopez2Bernardo A. Mainou3Yiting Zhang4Alvaro Whittembury5Alfredo Jose Olmedo Valarezo6Gonzalo Baquero7Rosa Romero de Aguinaga8Lucia Jeannete Zurita Salinas9Maria Gabriela Santacruz Mancheno10Diana Elizabeth Medina Chacho11Emmanuelle Quentin12Ana Elena Chevez13Gloria Rey-Benito14Ondrej Mach15University of San Francisco, Quito, EcuadorPolio Eradication Department, World Health Organization, Avenue Appia 20, CH-1211 Genève 27, Geneva, SwitzerlandUniversity of San Francisco, Quito, EcuadorDivision of Viral Diseases, Centres for Disease Control and Prevention, Atlanta, USADivision of Viral Diseases, Centres for Disease Control and Prevention, Atlanta, USAPan American Health Organization, EcuadorPan American Health Organization, EcuadorNational Polio Certification Commission, EcuadorNational Polio Certification Commission, EcuadorNational Polio Certification Commission, EcuadorMinistry of Public Health, EcuadorMinistry of Public Health, EcuadorUniversidad UTE, EcuadorImmunization Unit, Pan American Health Organization, Washington, USAImmunization Unit, Pan American Health Organization, Washington, USAPolio Eradication Department, World Health Organization, Avenue Appia 20, CH-1211 Genève 27, Geneva, Switzerland; Corresponding author.Summary: Background: In January 2018, Ecuador changed its routine immunization schedule by replacing one full dose of inactivated poliovirus vaccine (IPV) administered intramuscularly at 2 months of age with two doses of fractional IPV (1/5th of full dose, fIPV) administered intradermally at 2 and 4 months of age; and bivalent oral poliovirus vaccine (serotypes 1 and 3, bOPV) continues to be used. We compared seroprevalence and titres of polio antibodies achieved by the past and the current immunization schedules. Methods: This was a cross-sectional serological survey in children in Ecuador who received bOPV and either one IPV dose in 2017 or two fIPV doses in 2018. One blood sample was collected between October 2020 and March 2021 and analysed for presence of poliovirus neutralizing antibodies at CDC, Atlanta by microneutralization assay. Findings: We obtained 321 analysable samples from 329 (97·6%) enrolled children (160 received IPV and 161 fIPV). For serotype 2, seroprevalence was 50·0% (CI95%= 44·2-55·8%) for IPV and 83·2% (CI95%=78·5-87·1%) for fIPV recipients (p<0·001). Median antibody titers for serotype 2 were significantly lower for IPV than for fIPV recipients (3·0, CI95%= 3 – 3·5 vs. 4·8, CI95%= 4·5 – 5·2, p<0·001). Seroprevalence for serotypes 1 and 3 was above 90% and was not significantly different between IPV and fIPV recipients. Interpretation: Ecuador achieved significantly better poliovirus serotype 2 immunogenicity with two fIPV doses than with one IPV dose, while preserving vaccine supply and reducing costs. Our data provide further evidence that fIPV is a beneficial and potentially a cost-effective option in polio immunization. Funding: WHO obtained funds for the study from Rotary International.http://www.sciencedirect.com/science/article/pii/S2667193X22000527PoliomyelitisFractional dose inactivated poliovirus vaccineRoutine immunizationSeroprevalence assayEcuador |
| spellingShingle | Gabriel Trueba Vishali Jeyaseelan Lazaro Lopez Bernardo A. Mainou Yiting Zhang Alvaro Whittembury Alfredo Jose Olmedo Valarezo Gonzalo Baquero Rosa Romero de Aguinaga Lucia Jeannete Zurita Salinas Maria Gabriela Santacruz Mancheno Diana Elizabeth Medina Chacho Emmanuelle Quentin Ana Elena Chevez Gloria Rey-Benito Ondrej Mach Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey The Lancet Regional Health. Americas Poliomyelitis Fractional dose inactivated poliovirus vaccine Routine immunization Seroprevalence assay Ecuador |
| title | Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey |
| title_full | Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey |
| title_fullStr | Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey |
| title_full_unstemmed | Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey |
| title_short | Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey |
| title_sort | achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in ecuador results from a cross sectional serological survey |
| topic | Poliomyelitis Fractional dose inactivated poliovirus vaccine Routine immunization Seroprevalence assay Ecuador |
| url | http://www.sciencedirect.com/science/article/pii/S2667193X22000527 |
| work_keys_str_mv | AT gabrieltrueba achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT vishalijeyaseelan achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT lazarolopez achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT bernardoamainou achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT yitingzhang achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT alvarowhittembury achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT alfredojoseolmedovalarezo achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT gonzalobaquero achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT rosaromerodeaguinaga achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT luciajeannetezuritasalinas achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT mariagabrielasantacruzmancheno achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT dianaelizabethmedinachacho achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT emmanuellequentin achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT anaelenachevez achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT gloriareybenito achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey AT ondrejmach achievinghighimmunogenicityagainstpolioviruswithfractionaldosesofinactivatedpoliovirusvaccineinecuadorresultsfromacrosssectionalserologicalsurvey |